Priliximab

Drug Profile

Priliximab

Alternative Names: Anti-CD4 MAb; CEN 000029; Centara; cMT 412; MT 412

Latest Information Update: 01 Aug 2002

Price : $50

At a glance

  • Originator Centocor
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Crohn's disease; Heart transplant rejection; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis

Most Recent Events

  • 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson
  • 04 Aug 1999 No-Development-Reported for Multiple sclerosis in Sweden (IV)
  • 04 Aug 1999 No-Development-Reported for Multiple sclerosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top